Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy

BACKGROUND: Gd targets in quantity and quality sufficient for first application in patients. METHODS: Tb on peptide disintegration. RESULTS: Lu, was stable over 24 h in the presence of a stabilizer. CONCLUSIONS: in quality suitable for high-specific radiolabeling, relevant for future clinical application.